menu
    • menu

    Company profile for Angitia Biopharmaceuticals

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Angitia Biopharma is at the forefront of innovation in the biotechnology industry, dedicated to discovering and developing novel therapies to address unmet medical needs. Focused on advancing biologics and cutting-edge therapeutic solutions, the company combines rigorous scientific research with clinical expertise to enhance patient outcomes and contribute to global healthcare advancements. With a commitment to quality, safe...
    Angitia Biopharma is at the forefront of innovation in the biotechnology industry, dedicated to discovering and developing novel therapies to address unmet medical needs. Focused on advancing biologics and cutting-edge therapeutic solutions, the company combines rigorous scientific research with clinical expertise to enhance patient outcomes and contribute to global healthcare advancements. With a commitment to quality, safety, and efficacy, Angitia Biopharma is shaping the future of medicine by delivering transformative solutions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Angitia BiopharmaceuticalsChina Flag
    Country
    Country
    China
    Address
    Address
    188 Kaiyuan Avenue, 2F, Building 4, Guangzhou, Guangdong 510530
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.angitiabio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Angitia Biopharmaceuticals Announces $130 M Series D Financing
    Angitia Biopharmaceuticals Announces $130 M Series D Financing

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232886/0/en/Angitia-Biopharmaceuticals-Announces-130-Million-Series-D-Financing.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Angitia Doses 1st Patient in Ph 2 Trial for Osteogenesis Therapy
    Angitia Doses 1st Patient in Ph 2 Trial for Osteogenesis Therapy

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216764/0/en/Angitia-Biopharmaceuticals-Announces-Dosing-of-First-Participant-in-Phase-2-IDUN-Trial-of-AGA2115-for-the-Treatment-of-Osteogenesis-Imperfecta.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Angitia Pharma Completes Ph2 AGA2118 Enrollment in Osteoporosis
    Angitia Pharma Completes Ph2 AGA2118 Enrollment in Osteoporosis

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212633/0/en/Angitia-Biopharmaceuticals-Completes-Enrollment-of-Phase-2-ARTEMIS-Trial-Evaluating-AGA2118-for-the-Treatment-of-Osteoporosis.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Angitia Shares 1st Human Data on AGA2115 in Osteogenesis at ASBMR
    Angitia Shares 1st Human Data on AGA2115 in Osteogenesis at ASBMR

    08 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/08/3146019/0/en/Angitia-Biopharmaceuticals-Presents-First-in-Human-Data-on-AGA2115-for-Osteogenesis-Imperfecta-at-ASBMR-2025.html

    GLOBENEWSWIRE
    08 Sep 2025
    Share Share
    Angitia to Share AGA2115 Data in Osteogenesis Imperfecta at ASBMR
    Angitia to Share AGA2115 Data in Osteogenesis Imperfecta at ASBMR

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/19/3135605/0/en/Angitia-Biopharmaceuticals-to-Present-Data-on-AGA2115-for-Osteogenesis-Imperfecta-at-ASBMR-2025.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    Angitia Biopharmaceuticals Announces Topline Results of AGA2115
    Angitia Biopharmaceuticals Announces Topline Results of AGA2115

    12 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/12/3098209/0/en/Angitia-Biopharmaceuticals-Announces-Topline-Results-from-First-in-Human-Study-of-AGA2115-A-Bispecific-Antibody-for-the-Treatment-of-Osteogenesis-Imperfecta.html

    GLOBENEWSWIRE
    12 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search